1.3 Name of the analyzed genes or DNA/chromosome segments MKS1, TMEM216 (MKS2), TMEM67 (MKS3), CEP290 (MKS4), RPGRIP1L (MKS5), CC2D2A (MKS6), NPHP3 (MKS7), TCTN2 (MKS8), B9D1 (MKS9), B9D2 (MKS10), TMEM231 (MKS11), KIF14 (MKS12), TMEM107 (MKS13) and TMEM138, TMEM237.
OMIM# of the gene(s)
MKS1, MIM# 609883; TMEM216, MIM #613277, TMEM67, MIM# 609884; CEP290, MIM# 610142; RPGRIP1L, MIM# 610937; CC2D2A, MIM# 612013; NPHP3, MIM# 608002; TCTN2, MIM# 613885; B9D1, MIM# 614209; B9D2, MIM# 614175; TMEM231, MIM# 614949, KIF14, MIM# 611279; TMEM107, MIM# 616183; TMEM138, MIM# 614465; TMEM237, MIM# 614423.
Mutational spectrum
Data according to published literature and HGMD database (https:// portal.biobase-international.com).
Exact figures are still hard to provide on the contribution of each of the above genes to the total mutational load in Meckel-Gruber syndrome. Although there is evidence for further genetic heterogeneity, major MKS genes are MKS1, MKS3/TMEM67 and MKS6/ CC2D2A, followed by MKS4/CEP290. Although all kind of pathogenic variants (missense and nonsense mutations, splice site mutations, deletions and insertions) are present, the majority is truncating, whereas in MKS3 also missense mutations are frequent.
Although some genotype-phenotype correlations may allow for prioritization of genes in single cases, efficient testing has only been possible since establishment of next-generation sequencing (NGS) and the possibility of simultaneous investigation of all genes to be discussed in a fetus.
Analytical methods
In consanguineous and multiplex pedigrees, initial linkage analysis (targeted and genome-wide) with subsequent sequencing in case of compatible haplotypes is possible, but often replaced by sequencing now.
In sporadic cases originating from non-consanguineous marriages, direct sequencing (by Sanger's method or NGS) is usually performed due to private variants in most cases.
Analytical validation
(Potential) pathogenic variants are bidirectionally sequenced, preferentially on a second DNA sample of the index patient. Segregation analysis in the parents of the index patient to ensure compound heterozygosity and/or to exclude a large deletion on the other allele for a homozygous variant should be performed. In case of a novel variant, family studies of affected and non-affected persons can be helpful, as well as testing of ethnically matched controls to exclude a pathogenic variant. Gene transcripts should be analyzed in case of potential splicing variants.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence) 1/20 000.
If applicable, prevalence in the ethnic group of the investigated person
In Finland and other isolated and/or consanguineous cohorts, MKS is much more frequent.
(most probably 41/5000-10 000). 
Diagnostic setting
Yes No A. (Differential) diagnostics ⊠ □ B. Predictive testing □ ⊠ C. Risk assessment in relatives ⊠ □ D. Prenatal ⊠ □
TEST CHARACTERISTICS

Clinical sensitivity (proportion of positive tests if the disease is present)
Clinical sensitivity is not known so far. Currently, more than a dozen genes with a number of variants have been identified as the cause for Meckel syndrome. There is variation of the distribution of these variants in different populations, and additional genes can be expected to be identified in future years.
Clinical specificity (proportion of negative tests if the disease is not present)
A hallmark of ciliopathies is their significant clinical and genetic heterogeneity with considerable overlap between different entities. In particular, Meckel syndrome is allelic to a group of other ciliarelated disorders:
Joubert syndrome (CC2D2A, CEP290, RPGRIP1L, TCTN2, TMEM67, TMEM138, TMEM216, TMEM231, TMEM237) Bardet-Biedl syndrome (CEP290, MKS1) Nephronophthisis (CEP290, NPHP3, RPGRIP1L, TMEM67)
Recently, single fetuses with features of MKS were described with variants in EVC2 and EXOC4. The first fetus was found to carry a novel homozygous variant (in-frame insertion of eight amino acids) in EVC2, a gene usually described to cause the ciliopathy Ellis-van Crefeld syndrome (EVC). Typical features for EVC such as skeletal and cardiac findings were lacking in this individual. The other fetus was described to harbor a novel homozygous missense variant in EXOC4 that encodes an exocyst protein recruited to the basal body. Both of these fetuses were detected by exome sequencing and had consanguineous parents and were of Arab origin.
Positive clinical predictive value (life-time risk to develop the disease if the test is positive).
100%.
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
. In any case (index case tested or not), there is no risk to develop the disease for an unaffected individual (always present before birth).
3. CLINICAL UTILITY 3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.10 'A' was marked) Yes.
Can a diagnosis be made other than through a genetic test?
No □ (continue with 3.
Other (please describe) Autopsy and histological verification of the typical findings is reasonable.
Describe the burden of alternative diagnostic methods to the patient
The condition is usually lethal.
How is the cost effectiveness of alternative diagnostic methods to be judged?
Clinical work-up and imaging might be less cost-intensive, however, the obtained data is less clear with lower specificity and sensitivity.
Will disease management be influenced by the result of a genetic test?
No □ Yes ⊠ Therapy (please describe) Not relevant in lethal cases. Prognosis (please describe)
Usually lethal perinatally or in early infancy.
Management (please describe) Termination of pregnancy in prenatally diagnosed cases is an option for many couples.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked) 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
Early prenatal diagnostics and/or PGD become possible as well as carrier testing of family members.
Please note: due to the rarity of the disease, this is primarily important for couples that are related or of Finnish origin (eg, MKS1 founder mutation).
